Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLTO Galecto	$3.18 -1.4%	$3.45	$2.01 ▼ $14.82	$4.21M	1.35	114,671 shs	6,959 shs
HOTH Hoth Therapeutics	$1.18 -2.9%	$1.28	$0.65 ▼ $3.80	$15.58M	0.66	3.84 million shs	109,494 shs
IXHL Incannex Healthcare	$0.65 +4.9%	$0.48	$0.08 ▼ $3.12	$19.10M	7.67	65.89 million shs	79.34 million shs
LSB LakeShore Biopharma	$0.83 +3.3%	$0.94	$0.59 ▼ $8.60	$17.15M	0.56	126,711 shs	8,876 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLTO Galecto	-4.17%	-3.85%	-10.31%	+3.54%	-75.23%
HOTH Hoth Therapeutics	0.00%	-6.20%	-6.92%	+44.15%	+71.15%
IXHL Incannex Healthcare	-7.80%	+35.08%	-42.24%	+205.64%	-64.89%
LSB LakeShore Biopharma	+0.63%	-4.31%	-11.16%	-25.23%	-81.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GLTO Galecto	3.7749 of 5 stars	3.5	5.0	3.5	1.7	1.3
HOTH Hoth Therapeutics	2.8222 of 5 stars	3.5	5.0	2.5	0.0	0.6
IXHL Incannex Healthcare	0.234 of 5 stars	0.0	2.0	2.4	0.8	0.0
LSB LakeShore Biopharma	1.1792 of 5 stars	0.0	5.0	2.2	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLTO Galecto	3.00	Buy	$10.00	212.01% Upside
HOTH Hoth Therapeutics	3.00	Buy	$4.00	236.13% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
LSB LakeShore Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GLTO, IXHL, HOTH, and LSB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLTO Galecto	N/A	N/A	N/A	N/A	$7.26 per share	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.73 per share	N/A
IXHL Incannex Healthcare	$10K	1,921.78	N/A	N/A	$0.18 per share	3.63
LSB LakeShore Biopharma	$614.96M	0.03	N/A	N/A	$3.35 per share	0.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLTO Galecto	-$21.44M	-$13.13	N/A	N/A	N/A	N/A	-115.70%	-95.42%	11/7/2025 (Estimated)
HOTH Hoth Therapeutics	-$8.19M	-$1.07	N/A	N/A	N/A	N/A	-114.32%	-105.92%	11/11/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)
LSB LakeShore Biopharma	-$13.93M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest GLTO, IXHL, HOTH, and LSB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A
8/5/2025	Q2 2025	GLTO Galecto	N/A	-$2.60	N/A	-$2.60	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLTO Galecto	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
LSB LakeShore Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLTO Galecto	N/A	4.96	4.96
HOTH Hoth Therapeutics	N/A	27.54	27.54
IXHL Incannex Healthcare	N/A	2.12	2.12
LSB LakeShore Biopharma	0.05	1.02	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLTO Galecto	14.20%
HOTH Hoth Therapeutics	7.08%
IXHL Incannex Healthcare	0.43%
LSB LakeShore Biopharma	52.64%

Insider Ownership

Company	Insider Ownership
GLTO Galecto	10.80%
HOTH Hoth Therapeutics	6.92%
IXHL Incannex Healthcare	15.49%
LSB LakeShore Biopharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLTO Galecto	40	1.33 million	1.18 million	Optionable
HOTH Hoth Therapeutics	4	13.26 million	12.34 million	Not Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
LSB LakeShore Biopharma	773	20.77 million	N/A	N/A

GLTO, IXHL, HOTH, and LSB Headlines

Recent News About These Companies

LakeShore Biopharma Co., Ltd.: LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

August 28 at 5:38 PM | finanznachrichten.de

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

August 28 at 8:00 AM | prnewswire.com

LakeShore Biopharma receives non-binding acquisition proposal from Oceanpine

August 18, 2025 | msn.com

LakeShore Biopharma Just Got An Acquisition Proposal From Oceanpine Capital: More Details Inside

August 18, 2025 | msn.com

LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

August 18, 2025 | prnewswire.com

LakeShore Biopharma Reports FY2025 Financial Results with Improved Profitability

August 8, 2025 | theglobeandmail.com

LakeShore Biopharma Announces Fiscal Year 2025 Financial Results

July 31, 2025 | prnewswire.com

LakeShore Biopharma secures $15 million in private placement

July 10, 2025 | uk.investing.com

LakeShore Biopharma Announces US$15 Million Private Placement Financing

July 8, 2025 | prnewswire.com

LakeShore Biopharma Co., Ltd (LSB) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)

April 23, 2025 | prnewswire.com

LSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27th

February 6, 2025 | businesswire.com

LakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial Approval

December 19, 2024 | markets.businessinsider.com

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

December 19, 2024 | prnewswire.com

LakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

December 13, 2024 | finanznachrichten.de

LakeShore Biopharma Faces Challenges Amid Criminal Probe into Former Chairman

December 12, 2024 | markets.businessinsider.com

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

December 12, 2024 | globenewswire.com

LakeShore Biopharma Co Ltd Ordinary Shares

November 23, 2024 | morningstar.comM

LakeShore Biopharma Advances PIKA Rabies Vaccine Approval

November 8, 2024 | markets.businessinsider.com

LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan

November 7, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLTO, IXHL, HOTH, and LSB Company Descriptions

Galecto NASDAQ:GLTO

$3.18 -0.04 (-1.37%)

As of 03:27 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Hoth Therapeutics NASDAQ:HOTH

$1.18 -0.04 (-2.89%)

As of 03:47 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Incannex Healthcare NASDAQ:IXHL

$0.65 +0.03 (+4.85%)

As of 03:52 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

LakeShore Biopharma NASDAQ:LSB

$0.83 +0.03 (+3.25%)

As of 03:44 PM Eastern

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time